March 23, 2015
Amgen Astellas Biopharma K.K., a joint venture of Astellas Pharma and US-based Amgen, filed a new drug application in Japan on March 20 for evolocumab (development code: AMG145), an anti-PCSK9 monoclonal antibody for the treatment of hypercholesterolemia. Originated by Amgen,...read more